@article{oai:niigata-u.repo.nii.ac.jp:00014271,
 author = {伊東, 達雄},
 issue = {7},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Jul},
 note = {Effective pharmacotherapy in Alport syndrome has not yet been established. In this study, the efficiency of two immunosuppressants cyclosporin A (CyA) and mizoribine (MZR), and angiotensin converting enzyme inhibitor (ACEi), enalapril was examined using Col4 α 4 knockout mice as a model of this disease. CyA (10mg/kg/day), MZR (50mg/kg/day) and enalapril (18mg/kg/day) were administered everyday from three weeks of age. The CyA and enalapril treatments suppressed the elevation of proteinuria at 8 and 12 weeks of age and significantly inhibited the crescent formation at 12 weeks of age. The enalapril treatment could prolong the lives of Col4 α 4 mutant mice significantly, i.e, 26.3±6.2 weeks (mean±SD) of the treated mice vs. 18.3±3.9 weeks of the untreated control mice, whereas the CyA treatment failed to prolong the life span. Taken together, enalapril is considered to have a beneficial effect on the Alport model mice. This effect may be brought about by the improvement of renal hemodynamics and the suppression of an antiadhesion factor tenascin.},
 pages = {324--336},
 title = {アルポート症候群モデルマウスに対する薬物療法の検討},
 volume = {116},
 year = {2002}
}